Theralase Technologies Inc (TSV: TLT )
0.1850
-0.0100
(-5.13%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 24, 2025
Add to My Watchlist
All News about Theralase Technologies Inc
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Theralase(R) Expands Clinical Team
May 02, 2024
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
September 29, 2023
Theralase(R) Grants Stock Options
September 21, 2023
Theralase(R) Closes Private Placement Equity Financing
September 07, 2023
Theralase Release’s 2Q2023 Interim Financial Statements
August 29, 2023
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.